Aspergilloz

Yıl 2007, Cilt: 5 Sayı: 2, 62 - 69, 01.09.2007

Berna Aktürk Solmaz Çelebi Mustafa K. Hacımustafaoğlu

Öz

Aspergillus türleri, 900 den fazla türü olan, tüm dünyada çürüyen materyal üzerinde sık ve yaygın olarak bulunan saprofit bir mantar ailesidir. İnsanlarda invaziv hastalık, invaziv olmayan hastalık ve aşırı duyarlılık sendromu olmak üzere üçfarklı hastalık grubuna neden olurlar. Aspergillus türleri özellikle bağışıklık sisteminde sorun olan hastalarda ciddi enfeksiyonlara neden olan ve bağışıklık sistemini baskılayan ilaçların ve antibiyotiklerin yaygın olarak kullanılması ile önemi giderek artan enfeksiyonlara sebep olan mantarlardır. Bu yazıda özellikle invazif aspergilloz enfeksiyonunun patolojisi, patofizyolojisi, klinik tabloları, tanı ve tedavisi anlatılmaktadır

Anahtar Kelimeler

Aspergillozis, mantar, tedavi

Aspergillosis

Öz

Ubiquitous saprophytic molds, Aspergillus species are common on decaying material throughout the world. More than900 species are included in the genus Aspergillus. Among human beings 3 different clinical presentations including invasive disease, non-invasive disease and hypersensitivity reactions may occur due to Aspergillus species. Especially immunosuppressed patients are under the risk of invasive aspergillosis, and in consequence of extensive use of immunosuppresormedications and broad spectrum use of antibiotics, Aspergillus species gain importance among infectious diseases. In thisarticle, pathology, pathophysiology, clinical pictures, diagnosis and treatment of invasive aspergillosis are overwieved

Anahtar Kelimeler

Aspergillosis, fungus, treatment

Kaynakça

• 1. Kontoyiannis DP, Bodey GP. Invasive aspergillosis in 2002: an update. Eur J Clin Microbiol Infect Dis 2002;21:161-72.
• 2. Blum MD, Wiedermann BL. Aspergillus infections. In: Feigin RD, Cherry JD, Demmler GJ, Kaplan SL, eds. Textbook of Pediatric Infectious Diseases, 5th ed. Philadelphia, Saunders, 2004:2550-60.
• 3. Hajjeh RA, Warnock DW. Aspergillus species. In: Long SS, Pickering LK, Prober CG, eds. Principles and Practice of Pediatric Infectious Diseases, 2nd ed. Philadelphia: Churchill Livingstone, 2003:1213-20.
• 4. Denning DW. Aspergillus species. In: Mandell GL, Bennet JE, Dolin R, eds. Principles and Practice of Infectious Diseases, 5th ed. Philadelphia: Churchill Livingstone, 2000:2674-85.
• 5. Roilides E, Unlig K, Venzon D, et al. Prevention of corticosteroid-induced suppression of human polymorphonuclear leukocyte-induced damage of Aspergillus fumigatus hyphae by granulocyte colony-stimulating factor and gamma interferon. Infect Immun 1993;61:4870-7.
• 6. Roilides E, Blake C, Holmes A, et al. Granulocyte-macrophage colony-stimulating factor and interferon-γ prevent dexamethasone-induced immunosuppression of antifungal monocyte activity against Aspergillus fumigatus hyphae. J Med Vet Mycol 1996;34:63-9.
• 7. Allam MF, Del Castillo AS, Diaz-Molina C, Navajas RF. Invasive pulmonary aspergillosis: Identification of risk factors. Scand J Infect Dis 2002;34:819-22.
• 8. Muller FM, Trusen A, Weig M. Clinical manifestations and diagnosis of invasive aspergillosis in immunocompromised children. Eur J Pediatr 2002;161:563-74.
• 9. Segal BH, DeCarlo ES, Kwon-Chung KJ, et al. Aspergillus nidulans infection in chronic granulomatous disease. Medicine (Baltimore). 1998;77:345-54.
• 10. Choi SS, Milmoe GJ, Dinndorf PA, Quinones RR. Invasive Aspergillus sinusitis in pediatric bone marrow transplant patients: Evaluation and management. Arch Otolaryngol Head Neck Surg 1995;121:1188-92.
• 11. Kavanagh KT, Hughes WT, Parham DM, Chanin LR. Fungal sinusitis in immunocompromised children with neoplasms. Ann Otol Rhinol Laryngol 1991;100:331-6.
• 12. Panda NK, Balaji P, Chakrabarti A, Sharma SC, Reddy CEE. Paranasal sinus aspergillosis: Its categorization to develop a treatment protocol. Mycoses 2004;47:277-83.
• 13. Green M, Wald ER, Tzakis A, et al. Aspergillosis of the CNS in a pediatric liver transplant recipient: Case report and review. Rev Infect Dis 1991;13:653-7.
• 14. Robinson MR, Fine HF, Ross ML, Mont EK, Bryant-Greenwood PK, Hertle RW, Tisdale JF, Young NS, Zeichner SL, Van Waes C, Whitcup SM, Walsh TJ. Sino-orbital-cerebral aspergillosis in immunocompromised pediatric patients. Pediatr Infect Dis J 2000;19:1197-203.
• 15. Marr KA, Patterson T, Denning D. Aspergillosis. Pathogenesis, clinical manifestations, and therapy. Infect Dis Clin North Am. 2002;16:875-94.
• 16. Cuccia V, Galarza M, Monges J. Cerebral aspergillosis in children. Report of three cases. Pediatr Neurosurg 2000;33:43-8.
• 17. Barst RJ, Prince AS, Neu HC. Aspergillus endocarditis in children: Case report and review of the literature. Pediatrics 1981;68:73-8.
• 18. Kleiman MB. Echocardiography in Aspergillus endocarditis. Pediatrics 1982; 69:252-3.
• 19. Tack KJ, Rhame FS, Brown B, Thompson RC. Aspergillus osteomyelitis: Report of four cases and review of the literature. Am J Med 1982;73:295-300.
• 20. Dotis J, Roilides E. Osteomyelitis due to Aspergillus spp. in patients with chronic granulomatous disease: Comparison of Aspergillus nidulans and Aspergillus fumigatus. Int J Infect Dis 2004;8:103-10.
• 21. Panda A, Sharma N, Das G, Kumar N, Satpathy G. Mycotic keratitis in children: Epidemiologic and microbiologic evaluation. Cornea 1997;16:295-9.
• 22. Demicco DD, Reichman RC, Violette EJ, Winn WC Jr. Disseminated aspergillosis presenting with endophthalmitis. A case report and a review of the literature. Cancer 1984;53:1995-2001.
• 23. Smith JR, Chee SP. Endogenous Aspergillus endophthalmitis occurring in a child with normal immune function. Eye 2000;14:670-1.
• 24. Grossman ME, Fithian EC, Behrens C, et al. Primary cutaneous aspergillosis in six leukemic children. J Am Acad Dermatol 1985;12:313-8.
• 25. Walmsley S, Devi S, King S, et al. Invasive Aspergillus infections in a pediatric hospital: A ten-year review. Pediatr Infect Dis J 1993;12:673-82.
• 26. Papouli M, Roilides E, Bibashi E, Andreou A. Primary cutaneous aspergillosis in neonates: Case report and review. Clin Infect Dis 1996;22:1102-4.
• 27. van Burik JH, Colven R, Spach DH. Cutaneous aspergillosis. J Clin Microbiol 1998;36:3115-21.
• 28. Naidu J, Singh SM. Aspergillus chevalieri (Mangin) Thom and Church: A new opportunistic pathogen of human cutaneous aspergillosis. Mycoses 1994;37:271-4.
• 29. Finer G, Greenberg D, Leibovitz E, Leiberman A, Shelef I, Kapelushnik J.Conservative treatment of malignant (invasive) external otitis caused by Aspergillus flavus with oral itraconazole solution in a neutropenic patient. Scand J Infect Dis 2002;34:227-9.
• 30. British Tuberculosis and Thoracic Association. Aspergilloma and residual tuberculosis cavities-the results of a resurvey. Tubercle 1970;51:227-45.
• 31. Daly RC, Pairolero PC, Piehler JM, et al. Pulmonary aspergilloma. Results of surgical treatment. J Thorac Cardiovasc Surg 1986;92:981-8.
• 32. Aranoff SC. Aspergillus. In: Behrman RE, Kliegman RM, Jenson HB, eds. Nelson Textbook of Pediatrics. 17th edition, Philadelphia, WB Saunders Co. 2004:1016-8.
• 33. Suzuki K, Iwata S, Iwata H. Allergic bronchopulmonary aspergillosis in a 9-year-old boy. Eur J Pediatr 2002;161:408-9.
• 34. Kumar R. Mild, moderate, and severe forms of allergic bronchopulmonary aspergillosis: A clinical and serologic evaluation. Chest 2003;124:890-2.
• 35. Ragosta KG, Clayton JA, Cambareri CB, Domachowske JB. Allergic bronchopulmonary aspergillosis masquerading as pulmonary tuberculosis. Pediatr Infect Dis J 2004;23:582-4.
• 36. Kufltimur S. Aspergillus, Fusarium ve di¤er küf mantarlar›. ‹nfeksiyon Hastal›klar› ve Mikrobiyoloji, ed. Topçu AW, Söyletir G, Do¤anay M, 2. Bask›, Nobel T›p Kitabevleri, 2002:1833-40.
• 37. Dupont B. Overview of the lipid formulations of amphotericin B. J Antimicrob Chemother 2002;49(Suppl. S1):31-6.
• 38. Bertolone SJ, Gaviria JM. Amphotericin B lipid complex injection in the treatment of severe systemic mycoses. Int Pediatr 2001;16:48-61.
• 39. Tollemar J, Klingspor L, Ringden O. Liposomal amphotericin B (Ambisome) for fungal infections in immunocompromised adults and children. Clin Microbiol Infect 2001;7(Suppl 7):68- 79.
• 40. Keating GM, Jarvis B. Caspofungin. Drugs 2001;61:1121-9.
• 41. Walsh TJ, Teppler H, Donowitz GR, et al. Caspofungin versus liposomal amphotericin B for emprical antifungal therapy in patients with persistent fever and neutropenia. N Engl J Med 2004;351:1391-402.
• 42. Herbrecht R, Denning DW, Patterson TF, et al. Voriconozale versus amphotericin B for primary therapy of invasive aspergillosis. N Engl J Med 2002;347:408-15.
• 43. Johnson LB, Kauffman CA. Voriconazole: A new triazole antifungal agent. Clin Infect Dis 2003;36:630-7.
• 44. Arikan S, Rex JH. New agents for the treatment of systemic fungal infections-current status. Expert Opin Emerging Drugs 2002;7:3-32.
• 45. Sims-McCallum RP. Triple antifungal therapy for the treatment of invasive aspergillosis in a neutropenic pediatric patient. Am J Health-Syst Pharm 2003:60:2352-6.
• 46. Wright JA, Bradfield SM, Park JR, Hawkins DS. Prolonged survival after invasive aspergillosis: A single-institution review of 11 cases. J Pediatr Hematol Oncol 2003;25:286-91.
• 47. Gotzsche PC, Krogh Johansen H. Meta-analysis of prophylactic or empirical antifungal treatment versus placebo or no treatment in patients with cancer complicated by neutropenia. BMJ 1997;314:1238-44.
• 48. Pandya NA, Atra AA, Riley U, Pinkerton CR. Role of itraconazole in haematology/oncology. Arch Dis Child. 2003;88:258-60.
• 49. Uhlenbrock S, Zimmermann M, Fegeler W, Jurgens H, Ritter J. Liposomal amphotericin B for prophylaxis of invasive fungal infections in high-risk paediatric patients with chemotherapyrelated neutropenia: interim analysis of a prospective study. Mycoses 2001;44:455-63.
• 50. Drew RH, Dodds Ashley E, Benjamin DK Jr, Duane Davis R, Palmer SM, Perfect JR. Comparative safety of amphotericin B lipid complex and amphotericin B deoxycholate as aerosolized antifungal prophylaxis in lung-transplant recipients. Transplantation 2004;77:232-7.